AbbVie Inc. (ABBV)
| Market Cap | 326.97B |
| Revenue (ttm) | 54.40B |
| Net Income (ttm) | 5.99B |
| Shares Out | 1.77B |
| EPS (ttm) | 3.37 |
| PE Ratio | 54.94 |
| Forward PE | 15.78 |
| Dividend | $6.20 (3.35%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 5,352,706 |
| Open | 183.45 |
| Previous Close | 182.17 |
| Day's Range | 182.11 - 186.85 |
| 52-Week Range | 135.85 - 186.85 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 191.83 (+3.6%) |
| Earnings Date | Jul 25, 2024 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $191.83, which is an increase of 3.60% from the latest price.
News
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
Stocks on the move: Bristol Myers, Abbive, and Tesla
The Investment Committee discuss some of their stocks that are on the move today
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induct...
Stocks on the Move: Nasdaq, Warner Bros, Honeywell and Abbvie
The Investment Committee discuss some stocks on the move in today's market.
AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio
AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Hu...
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.
AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.
AbbVie lifts annual profit forecast on strong immunology drug sales
AbbVie raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter.
AbbVie's quarterly results top estimates as newer drugs cushion Humira's slide
AbbVie Inc. on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.
AbbVie Reports Second-Quarter 2024 Financial Results
Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 ...
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor
BOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock th...
Trade Tracker: Rob Sechan sells Bristol Myers and buys more Abbvie
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to discuss his latest moves. The Committee discuss the Healthcare sector.
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 throug...
Alzamend Neuro Announces Reverse Stock Split
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Reverse Stock Split.
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
NORTH CHICAGO, Ill. , July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D.
AbbVie cuts 2024 profit forecast on acquisition-related expenses
AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens.
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A.
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicu...
AbbVie Acquires Celsius Therapeutics
Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27...
Introducing Allē Payment Plans, Powered by Cherry
Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and ...
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
- EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)- Bispec...
US FDA declines to approve AbbVie's Parkinson's disease therapy
AbbVie said on Tuesday the U.S. Food and Drug Administration has rejected the company's marketing application for its therapy to treat motor fluctuations in adults with advanced Parkinson's disease.
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufac...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , June 21, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.